RAB32 promotes glioma cell progression by activating the JAK/STAT3 signaling pathway

Sinan Zhang,Xudong Jiang,Qing Wei,Liji Huang,Zhuoyan Huang,Lina Zhang
DOI: https://doi.org/10.1177/03000605241282384
2024-12-05
Journal of International Medical Research
Abstract:Journal of International Medical Research, Volume 52, Issue 12, December 2024. ObjectiveThis study aimed to investigate the role of RAB32 in glioblastomas and its molecular mechanisms that regulate gliomas.MethodsThe expression and prognostic value of RAB32 were evaluated using western blotting and the Gene Expression Profiling Interactive, Chinese Glioma Genome Atlas, and The Cancer Genome Atlas databases. Lentivirus containing sh-RAB32 or OE-RAB32 was used to manipulate RAB32 expression in glioma cells. The effects of RAB32 on cell proliferation, migration, and invasion were determined by western blotting, cell counting kit-8, plate cloning, wound healing, and transwell assays. Gene set enrichment analysis was used to screen for associations between the JAK/STAT3 signaling pathway and RAB32. The role of this pathway was verified using JAK/STAT3 inhibitors.ResultsRAB32 expression was significantly upregulated in patients with glioma and in glioma cell lines. The expression level was positively correlated with the glioma grade and served as an independent prognostic factor. In vitro experiments revealed that RAB32 knockdown inhibited glioblastoma cell proliferation, migration, and invasion, while the opposite effects were observed with overexpression and could be inhibited by the JAK/STAT3 inhibitor BP-1-102.ConclusionRAB32 promotes malignant progression of glioblastoma cells through the JAK/STAT signaling pathway, providing new possibilities for therapeutic targets for glioblastoma.
pharmacology & pharmacy,medicine, research & experimental
What problem does this paper attempt to address?